

## Chapter 90

### REFERENCES

1. Graff-Radford SB. Myofascial pain: diagnosis and management. *Curr Pain Headache Rep.* 2004;8:463-467.
2. Gordon D, Arend W. Rheumatic diseases. In: Cecil RL, Goldman L, Ausiello DA, eds. *Cecil Textbook of Medicine.* Philadelphia: Saunders; 2004.
3. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. *J Rheumatol Suppl.* 2005;75:6-21.
4. Arnold LM, Russell IJ, Diri EW, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. *J Pain.* 2008;9(9):792-805.
5. Arnold LM, Clauw DJ, Wohlreich MM, et al. Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo-controlled clinical trials. *Prim Care Companion J Clin Psychiatry.* 2009;11(5):237-244.
6. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. *J Rheumatol.* 2009;36(2):398-409. Erratum in: *J Rheumatol.* 2009;36(3):661.
7. Holman AJ. Fibromyalgia and pramipexole: promise and precaution. *J Rheumatol.* 2003;30:2733.
8. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. *Arthritis Rheum.* 2005;52:2495-2505.
9. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. *Arthritis Rheum.* 1998;41:778-799.
10. Sarzi-Puttini P, Cimmino MA, Scarpa R, et al. Osteoarthritis: an overview of the disease and its treatment strategies. *Semin Arthritis Rheum.* 2005;35(1 Suppl):1-10.
11. Poolsup N, Suthisisang C, Channark P, Kittikuluth W. Glucosamine long-term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials. *Ann Pharmacother.* 2005;39:1080-1087.
12. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. *N Engl J Med.* 2006;354:795-808.
13. Brandt KD, Mazzuca SA, Katz BP, et al. Effects of doxycycline on progression of osteoarthritis: results of a randomized, placebo-controlled, double-blind trial. *Arthritis Rheum.* 2005;52:2015-2025.
14. Waddell DD, Bricker DC. Clinical experience with the effectiveness and tolerability of Hylan G-F 20 in 1047 patients with osteoarthritis of the knee. *J Knee Surg.* 2006;19:19-27.
15. Kanner R. *Pain Management Secrets.* Philadelphia: Hanley & Belfus; 2003.
16. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. *Mayo Clin Proc.* 2010;85(3 Suppl):S3-S14.
17. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. *Arch Neurol.* 2003;60:1524-1534.
18. Mendell JR, Sahenk Z. Clinical practice. Painful sensory neuropathy. *N Engl J Med.* 2003;348:1243-1255.
19. Dyck PJ, Thomas PK. *Peripheral Neuropathy.* 4th ed. Philadelphia: WB Saunders; 2005.
20. Polydefkis M, Griffin JW, McArthur J. New insights into diabetic polyneuropathy. *JAMA.* 2003;290:1371-1376.
21. Gorson KC, Ropper AH. Idiopathic distal small fiber neuropathy. *Acta Neurol Scand.* 1995;92:376-382.
22. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care.* 2003;26:3160-3167.
23. Singleton JR, Smith AG, Russell J, Feldman EL. Polyneuropathy with impaired glucose tolerance: implications for diagnosis and therapy. *Curr Treat Options Neurol.* 2005;7:33-42.
24. Smith AG, Singleton JR. The diagnostic yield of a standardized approach to idiopathic sensory-predominant neuropathy. *Arch Intern Med.* 2004;164:1021-1025.
25. Davies M, Brophy S, Williams R, et al. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. *Diabetes Care.* 2006;29(7):1518-1522.
26. Eastman RN. *Neuropathy in diabetes in National Diabetes Data Group (U.S.), National Institute of Diabetes and Digestive and Kidney Diseases (U.S.), and National Institutes of Health (U.S.), Diabetes in America.* 2nd ed. NIH Publication No. 95-1468. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 1995.
27. Backonja M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. *JAMA.* 1998;280:1831-1836.
28. Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. *Diabetes Care.* 2004;27:1458-1486.

29. Ziegler D, Gries FA, Spüler M, Lessmann F. The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. *J Diabetes Complicat.* 1992;6:49-57.
30. Ziegler D, Gries FA, Spüler M, Lessmann F. The epidemiology of diabetic neuropathy. DiaCAN Multicenter Study Group. *Diabet Med.* 1993;10(2 Suppl):82S-86S.
31. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. *N Engl J Med.* 1993;329:977-986.
32. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. *Pain.* 2005;116:109-118.
33. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. *Pain Med.* 2005;6:346-356.
34. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. *Pain.* 2005;115:254-263.
35. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. *Neurology.* 2004;63:2104-2110.
36. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. *J Pain.* 2005;6:253-260.
37. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. *Pain.* 2004;110:628-638.
38. Beniczky S, Tajti J, Tímea Varga E, Vécsei L. Evidence-based pharmacological treatment of neuropathic pain syndromes. *J Neural Transm.* 2005;112:735-749.
39. Saarto T, Wiffen P. Antidepressants for neuropathic pain. *Cochrane Database Syst Rev.* 2005;CD005454.
40. Paradowski B, Bilinska M. [Gabapentin in the treatment of neuropathic pain in patients with type 2, diabetes mellitus]. *Pol Merkuriusz Lek.* 2003;15:61-64.
41. Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. *Pain.* 2004;110:697-706.
42. Lithner F. Venlafaxine in treatment of severe painful peripheral diabetic neuropathy. *Diabetes Care.* 2000;23:1710-1711.
43. Katz NP, Gammaitoni AR, Davis MW, Dworkin RH; Lidoderm Patch Study Group. Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial. *Pain Med.* 2002;3:324-332.
44. Scheffler NM, Sheitel PL, Lipton MN. Treatment of painful diabetic neuropathy with capsaicin 0.075%. *J Am Podiatr Med Assoc.* 1991;81:288-293.
45. Tandan R, Lewis GA, Krusinski PB, Badger GB, Fries TJ. Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up. *Diabetes Care.* 1992;15:8-14.
46. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. *Neurology.* 1998;50:1842-1846.
47. Harati Y, Gooch C, Swenson M, et al. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. *J Diabetes Complicat.* 2000;14:65-70.
48. Moulin D. Tramadol for the treatment of the pain of diabetic neuropathy. *Neurology.* 1999;52:1301.
49. Watson CP. The treatment of neuropathic pain: antidepressants and opioids. *Clin J Pain.* 2000;16(2 Suppl):S49-S55.
50. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlnden RL. Morphine, gabapentin, or their combination for neuropathic pain. *N Engl J Med.* 2005;352:1324-1334.
51. Hays L, Reid C, Doran M, Geary K. Use of methadone for the treatment of diabetic neuropathy. *Diabetes Care.* 2005;28:485-487.
52. Braune S. [Evidence-based pharmacotherapy of neuropathic pain syndromes]. *MMW Fortschr Med.* 2004;146:49-51.
53. Atli A, Dogra S. Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study. *Pain Med.* 2005;6:225-234.
54. Vinik A. Clinical review. Use of antiepileptic drugs in the treatment of chronic painful diabetic neuropathy. *J Clin Endocrinol Metab.* 2005;90:4936-4945.
55. Nicholson B. Treatment of painful polyneuropathies. *Curr Pain Headache Rep.* 2005;9:178-183.
56. Daousi C, Benbow SJ, MacFarlane IA. Electrical spinal cord stimulation in the long-term treatment of chronic painful diabetic neuropathy. *Diabet Med.* 2005;22:393-398.
57. Tesfaye S, Watt J, Benbow SJ, Pang KA, Miles J, MacFarlane IA. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. *Lancet.* 1996;348:1698-1701.
58. Hewitt DJ, McDonald M, Portenoy RK, Rosenfeld B, Passik S, Breitbart W. Pain syndromes and etiologies in ambulatory AIDS patients. *Pain.* 1997;70:117-123.
59. Katz N. Neuropathic pain in cancer and AIDS. *Clin J Pain.* 2000;16(2 Suppl):S41-S48.
60. Warfield CA, Bajwa ZH. *Principles and Practice of Pain Medicine.* 2nd ed. New York: McGraw-Hill; 2004:386-389.
61. Simpson DM, Olney R, McArthur JC, Khan A, Godbold J, Ebel-Frommer K. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. *Neurology.* 2000;54:2115-2119.
62. Simpson DM, McArthur JC, Olney R, et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. *Neurology.* 2003;60:1508-1514.
63. Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS. A randomized controlled trial. *JAMA.* 2004;291:63-70.
64. Amo C, Fernández-Gil S, Pérez-Fernández S, et al. [Carpal tunnel syndrome: clinical and neurophysiological correlation: review of 100, cases]. *Rev Neurol.* 1998;27:490-493.
65. Martinez-Albaladejo M, Nombela-Gomez M, Perez-Flores D. [With respect to Tinel and Phalen's signs]. *Ann Med Intern.* 1995;12:21-24.
66. Kost RG, Straus SE. Postherpetic neuralgia: pathogenesis, treatment, and prevention. *N Engl J Med.* 1996;335:32-42.
67. Ragozzino MW, Melton LJ 3rd, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. *Medicine (Baltimore).* 1982;61:310-316.

68. Guess HA, Broughton DD, Melton LJ 3rd, Kurland LT. Population-based studies of varicella complications. *Pediatrics*. 1986;78(4 Pt 2):723-727.
69. Rusthoven JJ. The risk of varicella-zoster infections in different patient populations: a critical review. *Transfus Med Rev*. 1994;8:96-116.
70. Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. *N Engl J Med*. 1991;325:1545-1550.
71. Broyer M, Tete MJ, Guest G, Gagnadoux MF, Rouzioux C. Varicella and zoster in children after kidney transplantation: long-term results of vaccination. *Pediatrics*. 1997;99:35-39.
72. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. *Proc R Soc Med*. 1965;58:9-20.
73. Dworkin RH, Portenoy RK. Proposed classification of herpes zoster pain. *Lancet*. 1994;343:1648.
74. Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. *Neurology*. 2004;62:1545-1551.
75. Balfour HH Jr. Varicella zoster virus infections in immunocompromised hosts. A review of the natural history and management. *Am J Med*. 1988;85(2A):68-73.
76. Jovanovic J, Cvjetković D, Pobor M, Brkić S. [Herpes zoster: treatment with acyclovir]. *Med Pregl*. 1997;50:305-308.
77. Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. A meta-analysis. *Arch Intern Med*. 1997;157:909-912.
78. Fields HL, Dubner R, Cervero F. Proceedings of the Fourth World Congress on Pain: Seattle. In: *Advances in Pain Research and Therapy*. Vol. 9. New York: Raven; 1985.
79. Winnie AP, Hartwell PW. Relationship between time of treatment of acute herpes zoster with sympathetic blockade and prevention of post-herpetic neuralgia: clinical support for a new theory of the mechanism by which sympathetic blockade provides therapeutic benefit. *Reg Anesth*. 1993;18:277-282.
80. Kumar V, Krone K, Mathieu A. Neuraxial and sympathetic blocks in herpes zoster and postherpetic neuralgia: an appraisal of current evidence. *Reg Anesth Pain Med*. 2004;29:454-461.
81. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. *Epileptic Disord*. 2004;6:57-75.
82. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. *Pain*. 2001;94:215-224.
83. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. *JAMA*. 1998;280:1837-1842.
84. Segal AZ, Rordorf G. Gabapentin as a novel treatment for postherpetic neuralgia. *Neurology*. 1996;46:1175-1176.
85. Sabatowski R, Gálvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. *Pain*. 2004;109:26-35.
86. Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. *Neurology*. 2003;60:1274-1283.
87. Frampton JE, Foster RH. Pregabalin: in the treatment of postherpetic neuralgia. *Drugs*. 2005;65:111-118.
88. Gammaitoni AR, Alvarez NA, Galer BS. Safety and tolerability of the lidocaine patch 5%, a targeted peripheral analgesic: a review of the literature. *J Clin Pharmacol*. 2003;43:111-117.
89. Galer BS, Jensen MP, Ma T, Davies PS, Rowbotham MC. The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled 3-week efficacy study with use of the neuropathic pain scale. *Clin J Pain*. 2002;18:297-301.
90. Kotani N, Kushikata T, Hashimoto H, et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. *N Engl J Med*. 2000;343:1514-1519.
91. Kikuchi A, Kotani N, Sato T, Takamura K, Sakai I, Matsuki A. Comparative therapeutic evaluation of intrathecal versus epidural methylprednisolone for long-term analgesia in patients with intractable postherpetic neuralgia. *Reg Anesth Pain Med*. 1999;24:287-293.
92. Forrest JB. The response to epidural steroid injections in chronic dorsal root pain. *Can Anaesth Soc J*. 1980;27:40-46.
93. Bates JA, Nathan PW. Transcutaneous electrical nerve stimulation for chronic pain. *Anaesthesia*. 1980;35:817-722.
94. van Slobbe AM, Bohnen AM, Bernsen RM, Koes BW, Bierma-Zeinstra SM. Incidence rates and determinants in meralgia paresthetica in general practice. *J Neurol*. 2004;251:294-297.
95. Nahabedian MY, Dellon AL. Meralgia paresthetica: etiology, diagnosis, and outcome of surgical decompression. *Ann Plast Surg*. 1995;35:590-594.
96. Grossman MG, Ducey SA, Nadler SS, Levy AS. Meralgia paresthetica: diagnosis and treatment. *J Am Acad Orthop Surg*. 2001;9:336-344.
97. The International Classification of Headache Disorders: 2nd edition. *Cephalalgia*. 2004;24(1 Suppl):9-160.
98. Cheshire WP Jr. Defining the role for gabapentin in the treatment of trigeminal neuralgia: a retrospective study. *J Pain*. 2002;3:137-142.
99. Backonja MM, Serra J. Pharmacologic management part I: better-studied neuropathic pain diseases. *Pain Med*. 2004;5(Suppl 1):S28-S47.
100. Kanpolat Y, Ugur HC. Systematic review of ablative neurosurgical techniques for the treatment of trigeminal neuralgia. *Neurosurgery*. 2005;57:E601.
101. Nickel J, Sonnenburg M, Scheufler O, Andresen R. [Eagle syndrome: diagnostic imaging and therapy]. *Rontgenpraxis*. 2003;55:108-113.
102. Hecht JS. Occipital nerve blocks in postconcussive headaches: a retrospective review and report of ten patients. *J Head Trauma Rehabil*. 2004;19:58-71.
103. Merskey DM. Classification of pain, descriptions of chronic pain syndromes and definitions of pain terms. *Pain*. 1986; (3 Suppl):S1-S226.
104. Andersen G, Vestergaard K, Ingeman-Nielsen M, Jensen TS. Incidence of central post-stroke pain. *Pain*. 1995;61:187-193.
105. Tasker RR, DeCarvalho GT, Dolan EJ. Intractable pain of spinal cord origin: clinical features and implications for surgery. *J Neurosurg*. 1992;77:373-378.
106. Vranken JH, Dijkgraaf MG, Kruis MR, et al. Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. *Pain*. 2008;136(1-2):150-157.
107. Vestergaard K, Andersen G, Gottrup H, Kristensen BT, Jensen TS. Lamotrigine for central poststroke pain: a randomized controlled trial. *Neurology*. 2001;56:184-190.

108. Finnerup NB, Sindrup SH, Bach FW, Johannesen IL, Jensen TS. Lamotrigine in spinal cord injury pain: a randomized controlled trial. *Pain*. 2002;96:375-383.
109. Stanton-Hicks M, Jänig W, Hassenbusch S, Haddox JD, Boas R, Wilson P. Reflex sympathetic dystrophy: changing concepts and taxonomy. *Pain*. 1995;63:127-133.
110. Loh L, Nathan PW. Painful peripheral states and sympathetic blocks. *J Neurol Neurosurg Psychiatry*. 1978;41:664-671.
111. Loh L, Nathan PW, Schott GD, Wilson PG. Effects of regional guanethidine infusion in certain painful states. *J Neurol Neurosurg Psychiatry*. 1980;43:446-451.
112. Loh L, Nathan PW, Schott GD. Pain due to lesions of central nervous system removed by sympathetic block. *Br Med J (Clin Res Ed)*. 1981;282:1026-1028.
113. Veldman PH, Reynen HM, Arntz IE, Goris RJ. Signs and symptoms of reflex sympathetic dystrophy: prospective study of 829 patients. *Lancet*. 1993;342:1012-1016.
114. Allen G, Galer BS, Schwartz L. Epidemiology of complex regional pain syndrome: a retrospective chart review of 134 patients. *Pain*. 1999;80:539-544.
115. Veldman PH, Goris RJ. Multiple reflex sympathetic dystrophy. Which patients are at risk for developing a recurrence of reflex sympathetic dystrophy in the same or another limb. *Pain*. 1996;64:463-466.
116. Philip PA, Philip M, Monga TN. Reflex sympathetic dystrophy in central cord syndrome: case report and review of the literature. *Paraplegia*. 1990;28:48-54.
117. Gellman H, Keenan MA, Stone L, Hardy SE, Waters RL, Stewart C. Reflex sympathetic dystrophy in brain-injured patients. *Pain*. 1992;51:307-311.
118. Schwartzman RJ, Kerrigan J. The movement disorder of reflex sympathetic dystrophy. *Neurology*. 1990;40:57-61.
119. An HS, Hawthorne KB, Jackson WT. Reflex sympathetic dystrophy and cigarette smoking. *J Hand Surg [Am]*. 1988;13:458-460.
120. Mailis A, Wade J. Profile of Caucasian women with possible genetic predisposition to reflex sympathetic dystrophy: a pilot study. *Clin J Pain*. 1994;10:210-217.
121. Bruhl S, Carlson CR. Predisposing psychological factors in the development of reflex sympathetic dystrophy. A review of the empirical evidence. *Clin J Pain*. 1992;8:287-299.
122. Janig W, Baron R. Complex regional pain syndrome: mystery explained? *Lancet Neurol*. 2003;2:687-697.
123. Janig W, Baron R. Complex regional pain syndrome is a disease of the central nervous system. *Clin Auton Res*. 2002;12:150-164.
124. Juottonen K, Gockel M, Silén T, Hurri H, Hari R, Forss N. Altered central sensorimotor processing in patients with complex regional pain syndrome. *Pain*. 2002;98:315-323.
125. Eisenberg E, Chistyakov AV, Yudashkin M, Kaplan B, Hafner H, Feinsod M. Evidence for cortical hyperexcitability of the affected limb representation area in CRPS. A psychophysical and transcranial magnetic stimulation study. *Pain*. 2005;113:99-105.
126. Harden RN, Bruhl S, Galer BS, et al. Complex regional pain syndrome: are the IASP diagnostic criteria valid and sufficiently comprehensive? *Pain*. 1999;83:211-219.
127. Fields HL. *Pain Syndromes in Neurology*. Philadelphia: Butterworths; 1990.
128. Galer BS, Bruhl S, Harden RN. IASP diagnostic criteria for complex regional pain syndrome: a preliminary empirical validation study. International Association for the Study of Pain. *Clin J Pain*. 1998;14:48-54.
129. Bruhl S, Harden RN, Galer BS, et al. External validation of IASP diagnostic criteria for complex regional pain syndrome and proposed research diagnostic criteria. International Association for the Study of Pain. *Pain*. 1999;81:147-154.
130. Reinders MF, Geertzen JH, Dijkstra PU. Complex regional pain syndrome type I. Use of the International Association for the Study of Pain diagnostic criteria defined in 1994. *Clin J Pain*. 2002;18:207-215.
131. Harden RN, Bruhl SP. Diagnostic criteria. In: Wilson PR, Stanton-Hicks M, Harden RN, eds. *CRPS: Current Diagnosis and Therapy. Progress in Pain Research and Management*. Seattle: IASP Press; 2005;32:316.
132. Rho RH, Brewer RP, Lamer TJ, Wilson PR. Complex regional pain syndrome. *Mayo Clin Proc*. 2002;77:174-180.
133. Kozin F, Sojin JS, Ryan LM, Carrera GF, Wortmann RL. Bone scintigraphy in the reflex sympathetic dystrophy syndrome. *Radiology*. 1981;138:437-443.
134. Bruhl S, Lubenow TR, Nath H, Ivankovich O. Validation of thermography in the diagnosis of reflex sympathetic dystrophy. *Clin J Pain*. 1996;12:316-325.
135. Stanton-Hicks MD, Burton AW, Bruhl SP, et al. An updated interdisciplinary clinical pathway for CRPS. Report of an expert panel. *Pain Practice*. 2002;2:1-16.
136. Quisel A, Gill JM, Witherell P. Complex regional pain syndrome: which treatments show promise? *J Fam Pract*. 2005;54:599-603.
137. Oerlemans HM, Oostendorp RA, de Boo T, van der Laan L, Severens JL, Goris JA. Adjuvant physical therapy versus occupational therapy in patients with reflex sympathetic dystrophy/complex regional pain syndrome type I. *Arch Phys Med Rehabil*. 2000;81:49-56.
138. Yung Chung O, Bruhl SP. Complex regional pain syndrome. *Curr Treat Options Neurol*. 2003;5:499-511.
139. Christensen K, Jensen EM, Noer I. The reflex dystrophy syndrome response to treatment with systemic corticosteroids. *Acta Chir Scand*. 1982;148:653-655.
140. Kingery WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. *Pain*. 1997;73:123-139.
141. Rocco AG. Radiofrequency lumbar sympathectomy. The evolution of a technique for managing sympathetically maintained pain. *Reg Anesth*. 1995;20:3-12.
142. Taylor RS, Van Buyten JP, Buchser E. Spinal cord stimulation for complex regional pain syndrome: a systematic review of the clinical and cost-effectiveness literature and assessment of prognostic factors. *Eur J Pain*. 2006;10:91-101.
143. Kemler MA, Barendse GA, van Kleef M, et al. Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. *N Engl J Med*. 2000;343:618-624.
144. Von Eisenhart-Rothe R, Rittmeister M. [Drug therapy in complex regional pain syndrome type I]. *Orthopade*. 2004;33:796-803.
145. Nambi-Joseph P, Stanton-Hicks M, Sferra JJ. Interventional modalities in the treatment of complex regional pain syndrome. *Foot Ankle Clin*. 2004;9:405-417.
146. Woodhouse A. Phantom limb sensation. *Clin Exp Pharmacol Physiol*. 2005;32:132-134.

147. Wu J, Chiu DT. Painful neuromas: a review of treatment modalities. *Ann Plast Surg.* 1999;43:661-667.
148. Wilder-Smith CH, Hill LT, Laurent S. Postamputation pain and sensory changes in treatment-naive patients: characteristics and responses to treatment with tramadol, amitriptyline, and placebo. *Anesthesiology.* 2005;103:619-628.
149. Adeniyi A. International Association for the Study of Pain—Ninth World Congress 22-27, August 1999, Vienna, Austria. *IDrugs.* 1999;2:1127-1129.
150. Schug SA, Burrell R, Payne J, Tester P. Preemptive epidural analgesia may prevent phantom limb pain. *Reg Anesth.* 1995;20:256.
151. Andersson GB. Epidemiology of low back pain. *Acta Orthop Scand Suppl.* 1998;281:28-31.
152. Andersson GB. Epidemiological features of chronic low-back pain. *Lancet.* 1999;354:581-585.
153. Bovim G, Schrader H, Sand T. Neck pain in the general population. *Spine.* 1994;19:1307-1309.
154. Lim CH, Jee WH, Son BC, Kim DH, Ha KY, Park CK. Discogenic lumbar pain: association with MR imaging and CT discography. *Eur J Radiol.* 2005;54:431-437.
155. Resnick DK, Malone DG, Ryken TC. Guidelines for the use of discography for the diagnosis of painful degenerative lumbar disc disease. *Neurosurg Focus.* 2002;13:E12.
156. Wetzel FT, McNally TA. Treatment of chronic discogenic low back pain with intradiscal electrothermal therapy. *J Am Acad Orthop Surg.* 2003;11:6-11.
157. Deen HG, Fenton DS, Lamer TJ. Minimally invasive procedures for disorders of the lumbar spine. *Mayo Clin Proc.* 2003;78:1249-1256.
158. Shah RV, Lutz GE, Lee J, Doty SB, Rodeo S. Intradiscal electrothermal therapy: a preliminary histologic study. *Arch Phys Med Rehabil.* 2001;82:1230-1237.
159. Carette S, Leclaire R, Marcoux S, et al. Epidural corticosteroid injections for sciatica due to herniated nucleus pulposus. *N Engl J Med.* 1997;336:1634-1640.
160. McLain RF, Kapural L, Mekhail NA. Epidural steroid therapy for back and leg pain: mechanisms of action and efficacy. *Spine J.* 2005;5:191-201.
161. Kolstad F, Leivseth G, Nygaard OP. Transforaminal steroid injections in the treatment of cervical radiculopathy. A prospective outcome study. *Acta Neurochir (Wien).* 2005;147:1065-1070.
162. Rathmell JP, Aprill C, Bogduk N. Cervical transforaminal injection of steroids. *Anesthesiology.* 2004;100:1595-1600.
163. Vad VB, Bhat AL, Lutz GE, Cammisa F. Transforaminal epidural steroid injections in lumbosacral radiculopathy: a prospective randomized study. *Spine.* 2002;27:11-16.
164. Lutz GE, Vad VB, Wisneski RJ. Fluoroscopic transforaminal lumbar epidural steroids: an outcome study. *Arch Phys Med Rehabil.* 1998;79:1362-1366.
165. Bogduk N, Marsland A. The cervical zygapophysial joints as a source of neck pain. *Spine.* 1988;13:610-617.
166. Cavanaugh JM, Ozaktay AC, Yamashita HT, King AI. Lumbar facet pain: biomechanics, neuroanatomy and neurophysiology. *J Biomech.* 1996;29:1117-1129.
167. Pevsner Y, Shabat S, Catz A, Folman Y, Gepstein R. The role of radiofrequency in the treatment of mechanical pain of spinal
168. McDonald GJ, Lord SM, Bogduk N. Long-term follow-up of patients treated with cervical radiofrequency neurotomy for chronic neck pain. *Neurosurgery.* 1999;45:61-67.
169. Cohen SP, Abdi S. Lateral branch blocks as a treatment for sacroiliac joint pain: a pilot study. *Reg Anesth Pain Med.* 2003;28:113-119.
170. Truumees E. Spinal stenosis: pathophysiology, clinical and radiologic classification. *Instr Course Lect.* 2005;54:287-302.
171. Yuan PS, Booth RE Jr, Albert TJ. Nonsurgical and surgical management of lumbar spinal stenosis. *Instr Course Lect.* 2005;54:303-312.
172. Gibson JN, Waddell G. Surgery for degenerative lumbar spondylosis. *Cochrane Database Syst Rev.* 2005;CD001352.
173. Bambakidis NC, Feiz-Erfan I, Klopfenstein JD, Sonntag VK. Indications for surgical fusion of the cervical and lumbar motion segment. *Spine.* 2005;30(16 Suppl):S2-S6.
174. Chagas H, Domingues F, Aversa A, Vidal Fonseca AL, de Souza JM. Cervical spondylotic myelopathy: 10 years of prospective outcome analysis of anterior decompression and fusion. *Surg Neurol.* 2005;64(Suppl 1):S1:30-S1:35.
175. Roh JS, Teng AL, Yoo JU, Davis J, Furey C, Bohlman HH. Degenerative disorders of the lumbar and cervical spine. *Orthop Clin North Am.* 2005;36:255-262.
176. Waguespack A, Schofferman J, Slosar P, Reynolds J. Etiology of long-term failures of lumbar spine surgery. *Pain Med.* 2002;3:18-22.
177. Viesca CO, Racz GB, Day MR. Special techniques in pain management: lysis of adhesions. *Anesthesiol Clin North Am.* 2003;21:745-766, vi.
178. Heavner JE, Racz GB, Raj P. Percutaneous epidural neuroplasty: prospective evaluation of 0.9% NaCl versus 10% NaCl with or without hyaluronidase. *Reg Anesth Pain Med.* 1999;24:202-207.
179. Taylor RJ, Taylor RS. Spinal cord stimulation for failed back surgery syndrome: a decision-analytic model and cost-effectiveness analysis. *Int J Technol Assess Health Care.* 2005;21:351-358.
180. North RB, Kidd DH, Olin J, et al. Spinal cord stimulation for axial low back pain: a prospective, controlled trial comparing dual with single percutaneous electrodes. *Spine.* 2005;30:1412-1418.
181. Taylor RS, Van Buyten JP, Buchser E. Spinal cord stimulation for chronic back and leg pain and failed back surgery syndrome: a systematic review and analysis of prognostic factors. *Spine.* 2005;30:152-160.
182. Bogduk N, Lord SM. Cervical spine disorders. *Curr Opin Rheumatol.* 1998;10:110-115.
183. Lord SM, Barnsley L, Wallis BJ, Bogduk N. Chronic cervical zygapophysial joint pain after whiplash. A placebo-controlled prevalence study. *Spine.* 1996;21:1737-1744.
184. Ronnen HR, de Korte PJ, Brink PR, van der Bijl HJ, Tonino AJ, Franke CL. Acute whiplash injury: is there a role for MR imaging? A prospective study of 100 patients. *Radiology.* 1996;201:93-96.
185. Nordemar R, Thorner C. Treatment of acute cervical pain: a comparative group study. *Pain.* 1981;10:93-101.
186. Wallis BJ, Lord SM, Bogduk N. Resolution of psychological distress of whiplash patients following treatment by radiofrequency neurotomy: a randomised, double-blind, placebo-controlled trial. *Pain.* 1997;73:15-22.

187. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Headache Classification Committee of the International Headache Society. *Cephalalgia*. 1988;8(7 Suppl):1-96.
188. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population: a prevalence study. *J Clin Epidemiol*. 1991;44:1147-1157.
189. Silberstein SD, Lipton RB, Goadsby PJ. *Headache in Clinical Practice*. Oxford, UK: Oxford University Press; 1998.
190. Practice parameter: the electroencephalogram in the evaluation of headache (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 1995;45:1411-1413.
191. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2000;55:754-762.